Talk:Cytomegalovirus

From Wikipedia, the free encyclopedia
Jump to: navigation, search
WikiProject Viruses (Rated B-class, High-importance)
WikiProject icon This article is within the scope of WikiProject Viruses, a collaborative effort to improve the coverage of viruses on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.
B-Class article B  This article has been rated as B-Class on the project's quality scale.
 High  This article has been rated as High-importance on the project's importance scale.
 
WikiProject Medicine / Dermatology  (Rated B-class, Mid-importance)
WikiProject icon This article is within the scope of WikiProject Medicine, which recommends that this article follow the Manual of Style for medicine-related articles and use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.
B-Class article B  This article has been rated as B-Class on the project's quality scale.
 Mid  This article has been rated as Mid-importance on the project's importance scale.
Taskforce icon
This article is supported by the Dermatology task force.
 

CMV in humans[edit]

The "CMV in Humans" (to the end of the article) was taken pretty much verbatim from a Centers for Disease Control and Prevention document, entitled Cytomegalovirus (CMV) Infection.

As far as I can see, this is a public domain document.

I took a bit of POV out, though it's clearly oriented from the point of view of how to best manage the disease. Have at it! Rholton

CMV is not the most common agent of infection, so I removed that sentence. EBV has higher antibody prevalence rates; more fundamentally, the statement does not make sense as there are bacteria that can be found in 100% of the population (e.g., coag-negative staph) that are sometimes responsible for opportunistic infections.

From Wikipedia:Peer Review:

The U.S. government is listed on Wikipedia:Public domain resources. There is a caveat or two, so check that page for more information. Unless CMV also has significant effects on animals, you should remove the heading ===CMV in humans=== and upgrade all subsequent headings as appropriate. More importantly, some separation should probably be made between descriptive content and lists of advice. People are generally averse to having instructive content on the wiki. I think that this is a case where it can stay, but only if it's separated out into a section of its own. -Smack 19:04, 8 Dec 2003 (UTC)

The statement that CMV infection exhausts the immune system by old age needs elaboration and sources. As it exists now, it is too vague and confusing and should be removed. —Preceding unsigned comment added by 76.226.55.247 (talk) 01:07, August 28, 2007 (UTC)

Sexually transmitted disease category[edit]

While CMV may be sexually transmitted, my bias is that the category should include only those diseases that are classically considered STDs, e.g. gonorrhea, chlamydia, syphyllis, etc. Otherwise, to be consistent, the category should also include diseases that are not conventionally categorized as STDs like hepatitis C, etc. Andrew73 22:10, 6 December 2005 (UTC)

Methods of contraction[edit]

Since this is herpes, would that mean it is easily contracted through saliva? In this case, kissing might be a big method of transferring it. Depending on how much of a factor it is (other environmental, or prenatal contraction), perhaps avoiding some of these physical methods of social connection would greatly extend human lifespans, until we find better methods of extending T-cell function so Cytomegalovirus doesn't take up all our immune resources. Tyciol 18:23, 12 December 2006 (UTC)

Merge proposal[edit]

HCMV (human cytomegalovirus) is redundant. Axl 21:10, 10 June 2007 (UTC)

Agree G716 21:50, 16 June 2007 (UTC)
Okay, I've done it. Axl 07:06, 20 June 2007 (UTC)

added reference[edit]

Ozkan TB, Mistik R, Dikici B, Nazlioglu HO.(2006) "Antiviral therapy in neonatal cholestatic cytomegalovirus hepatitis". BMC Gastroenterology 7:9. PMID: 17355631 [free full text at http://www.biomedcentral.com/1471-230X/7/9]

Looks like the history page automatically documented this, so I guess this note is just clutter. (Sorry... very new at this...)

Should there be greater emphasis on the effect cytomegalovirus has in unnecessarily choking the immune system, and compromising its performance in the elderly ? If so, it is a major contributor to unwanted inflammation, and premature aging. The issues are outlined at: http://www.fightaging.org/archives/001057.php —Preceding unsigned comment added by 116.240.172.135 (talk) 22:32, 11 February 2008 (UTC)



Feel free to delete. I would take care of it, but do not see a delete button.


Pinnpict (talk) 06:34, 8 February 2008 (UTC)

how about including mention of Cytomegalovirus/herpesvirus and carotid atherosclerosis: The aric study. and other recent studies. —Preceding unsigned comment added by 124.178.61.185 (talk) 06:31, 15 May 2009 (UTC)

Please note that the virion structural schematic is incomplete - the virion particle needs a tegument between the envelope and nucleocapsid - see for example Gandhi and Khanna, Lancet Infectious Diseases 2004 4:725-38 HM —Preceding unsigned comment added by 90.210.196.164 (talk) 12:51, 28 February 2010 (UTC)

CMV and glioblastoma recurrence[edit]

CMV has been linked to recurrence of glioblastoma following radio/chemo.

One report was in SciAm 'Mind' issue on brain.

One report has Scand. work on an anti-viral as promising for glioblastoma (adding a few months to average survival)

Given glioblastoma prevalence and morbidity, perhaps the importance of this article should be bumped up.

(JVI) http://jvi.asm.org/cgi/content/full/81/19/10424

(NEJM) Prins RM, Cloughesy TF, Liau LM The New England Journal of Medicine 2008, 359(5):539-41 on a clinical trial

(NIH 2007) http://www.ncbi.nlm.nih.gov/pubmed/17652378

(Duke U 2008 trial, on-going in 2010) http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00693095

A current clinical trial on survival times: (Baylor 2010 - starting 11/2010) http://clinicaltrialsfeeds.org/clinical-trials/show/NCT01205334 —Preceding unsigned comment added by Grshiplett (talkcontribs) 14:09, 31 October 2010 (UTC)

G. Robert Shiplett 13:59, 31 October 2010 (UTC)i
Inhibition of cytomegalovirus replication by inhibitors of (glucose to fatty acid conversion enzymes)

HCMV = human cytomegalovirus

ACC = acetyl-CoA carboxylase (catalyzes the conversion of acetyl-CoA into malonyl-CoA, requires biotin, http://en.wikipedia.org/wiki/Acetyl-CoA_carboxylase)
TOFA = 5-tetradecyloxy-2-furoic acid
C75 = trans-4-carboxy-5-octyl-3-methylene-butyrolactone
FAS = fatty acid synthase

Treatment (10 mg ml-1) with 5-tetradecyloxy-2-furoic acid (TOFA), an ACC inhibitor, resulted in a more than 1000-fold reduction in HCMV replication. C75 (trans-4-carboxy-5-octyl-3-methylene-butyrolactone), an inhibitor of FAS, resulted in a more than 100-fold effect at the same dose enzymes that build fatty acids, acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS)(http://www.eurekalert.org/pub_releases/2008-09/uorm-ead092608.php)

Many viruses, including influenza, HIV and hepatitis, use those same fatty acids to build instead their viral envelopes, outer coatings that help them penetrate human cells.
To investigate whether this requirement extended to other enveloped viruses, the team measured influenza A replication in the presence of the same TOFA and FAS inhibitors, and found similar reductions in replication. Influenza A has little in common with HCMV except for its lipid envelope.
Extensive clinical testing would be needed to draw conclusions about the safety of TOFA and C75, or similar compounds, as antiviral treatment. That said, the team took an early look at toxicity, exposing uninfected fibroblasts to C75 or TOFA for 96 hours. They found that the drugs blocked HCMV replication without causing cell toxicity or self-destruction (apoptosis).